Cognitive Behavioral Therapy and Naltrexone for Cocaine Dependence Joy M. Schmitz, Ph.D. Substance Abuse Research Center University of Texas Medical School.

Slides:



Advertisements
Similar presentations
TRI science addiction Lost Opportunity? SBI for Substance Abuse In ERs and Trauma Centers Academy Health Mady Chalk, Ph.D. Treatment Research Institute.
Advertisements

Medication-Assisted Therapy
Telephone Continuing Care James R. McKay, Ph.D. Center on the Continuum of Care in the Addictions Department of Psychiatry University of Pennsylvania Philadelphia.
13 Principles of Effective Addictions Treatment
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Integrated Dual Diagnosis Treatment
WEST EDINBURGH SUPPORT TEAM 27 th OCTOBER 2005 Malcolm Laing.
A MERICAN P SYCHOLOGICAL A SSOCIATION 11. Forensic Issues II.
Why Bother? It’s in Your Head Slay the Dragon Talk.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Recreational Therapy: An Introduction Chapter 5: Substance Use Disorders PowerPoint Slides.
Copyright Alcohol Medical Scholars Program1 Pathological Gambling and Alcohol Use Disorders Timothy W. Fong MD UCLA Gambling Studies Program Alcohol Medical.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
November 16, 2012Harm Reduction Conference1 Cannabis as a facilitator of mindfulness: Implications for the treatment of addiction. Amanda Reiman, PhD MSW.
Rehabilitation Programs and Office Follow-up Steven R. Ey, M.D. Medical Director Genesis Chemical Dependency Unit South Coast Medical Center Laguna Beach,
+ Module Four: Patient/Family Education and Self-Management At the end of this module, the participant will be able to: Describe three learning needs of.
Causes and Treatment of Substance Use Disorders Chapter 11.
Practical Application of Contingency Management Michael J. McCann, MA Matrix Institute on Addictions.
SUBSTANCE USE DISORDERS GENERAL METHODS OF TREATMENT Inpatient Detoxification and Rehabilitation Outpatient Individual, Couple, or Family Counseling Self-help.
Models of Treatment and Education with DUI Offenders
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
Substance Use Disorders: Treatment
Evidence-Based Practice: Psychosocial Interventions Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM NIDA Blending Conference June 3, 2008 Cincinnati, Ohio.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Substance Abuse Prevention Facts About Substance Abuse  Alcoholism is considered the third most prevalent public health problem in the United States today.
Responding to Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
Competency of Psychiatry Residents in the Treatment of Severe Mental Illness Before and After a Psychiatric Rehabilitation Community Rotation Melinda Randall.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
Recovery Support Services and Client Outcomes: What do the Data Tell Us? Recovery Community Services Program Grantee Meeting December 14, 2007.
EMPIRICALLY-SUPPORTED TREATMENTS FOR STIMULANT DEPENDENCE RICHARD A. RAWSON, Ph.D. UCLA INTEGRATED SUBSTANCE ABUSE PROGRAMS (ISAP) October 9, 2004.
Raymond F. Anton, MD for The COMBINE Study Research Group
Research Proposal John Miller Nicolette Edenburn Carolyn Cox.
A Proposed Research Plan Capella University Beth Jones July 2014.
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Recovery Support Services and Client Outcomes: Results of Two Interim Evaluations in Texas College on Problems of Drug College on Problems of Drug Dependence.
A Quick Overview of Evidence-Based Practice Manuals The Addiction Technology Transfer Center Network Funded by Substance Abuse and Mental Health Services.
Cognitive Behavioral Therapy Enduring Effects and Mechanisms Bruce J. Rounsaville Yale University.
California Addiction Training and Education Series Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute on Addictions Methamphetamine Behavioral.
TREATMENT OF SUBSTANCE USE DISORDERS TX myths 1. Nothing works 2. One approach is superior to all others (“one true light” tradition) 3. All treatment.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Substance Abuse Spring Substance-Related Disorders Substance abuse Substance dependence –Tolerance –Withdrawal Substance intoxication 2 Define substance.
Principles of Effective Drug Addiction Treatment Health 10 The Truth About Drugs Ms. Meade.
Background and Rationale for COMBINE A Multisite Clinical Trial Sponsored by National Institute on Alcohol Abuse and Alcoholism NIH, DHHS Margaret E. Mattson,
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
Moral / Temperance ModelAddiction as Sin or Crime Personal Irresponsibility Disease Model Genetic and Biological Factors ** 12-Step Framework; Abstinence.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Trends in Access to Substance Abuse Treatment for Women and Men: Jeanne C. Marsh, PhD, Hee-Choon Shin, PhD, Dingcai Cao, PhD University of Chicago.
DR. FORRY J.BEN PSYCHIATRIC RESIDENT 1DR. FORRY J.BEN 2015.
CHAPTER 10: Retaining Sobriety
Substance Use and Aging
CHAPTER 7: Relapse Prevention in the Treatment of Substance Abuse and Addiction Substance Abuse and Addiction Treatment: Practical Application of Counseling.
Drugs and Neuron Communication
Types of Intervention.
Babson, et al., in progress Isabella Romero
A systematic review of the relationship between substance abuse and psychotropic medication adherence: opportunities to improve outcomes for patients with.
PCN 501 Competitive Success-- snaptutorial.com
PCN 501 Education for Service-- snaptutorial.com
PCN 501 Teaching Effectively-- snaptutorial.com
PCN 501 knowledge is divine-- snaptutorial.com. PCN 501 Week 1 Assignment Comparison of Theories Paper For more classes visit Comparison.
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Treating Alcohol Abuse
Integrated Treatment for Co-Occurring Disorders
Cognitive/Behavioral Therapy for Addictions
Developing and Using a Referral Network
Integrated Treatment for Co-Occurring Disorders
Presentation transcript:

Cognitive Behavioral Therapy and Naltrexone for Cocaine Dependence Joy M. Schmitz, Ph.D. Substance Abuse Research Center University of Texas Medical School Houston Supported by NIDA (DA-09262, DA-6143, DA-15801) APA 2004

Why Combine Behavior Therapy and Medication?  For the treatment of cocaine dependence, little benefit from pharmacotherapy or psychotherapy alone  Each form of treatment may address distinct symptom areas, providing broader coverage  Offset the potential drawbacks associated with either treatment  Patient heterogeneity leads to differential response to treatment

Study Design Pharmacotherapy (Naltrexone) 0 mg 50 mg Psycho- Therapy Drug Counseling (DC) Relapse Prevention (RP)

Pharmacotherapy  Naltrexone Opiate antagonists attenuate cocaine's euphoric effects (Bain & Kornetsky, 1986; Kosten et al., 1992; Hubbell & Reid, 1995; Reid et al., 1993; 1996) Opiate antagonists decrease cocaine self-administration (DeVry et al., 1989; Mello et al., 1990; Ramsey & vanRee, 1991; Corrigall & Coen, 1991; Reid et al., 1995; 1996; 1997) Opiate antagonist treatment associated with lower rates of cocaine use (Kosten et al., 1989; Rosen & Kosten, 1991)

Psychotherapy  Relapse Prevention (RP) Coping Skills Relapse Prevention Theory (Marlatt & Gordon, 1985) Components include functional analysis of situational factors associated with craving or drug use, self- monitoring and specific home practice exercises, general lifestyle modifications, handling a lapse training.  Drug Counseling (DC) General education, nondirective support, encouragement for abstinence-oriented behaviors (Woody et al., 1983; Luborsky et al., 1982) Components include assessment of problem areas (e.g., health, family, vocation), education about recovery, crisis management.

Therapy Adherence

Retention Log Rank Statistic = 1.72, df = 3, p =.63.

Cocaine Use Therapy x Medication x Time: F (2, 60) = 3.69, p < *

Does homework compliance predict outcome?  Cognitive-behavioral psychotherapies are based on the premise that clients are more likely to improve if they apply skills learned in treatment to situations outside treatment (i.e., homework).  The relationship between homework compliance and treatment outcome is reliable and robust across different client problems (Kazantzis et al., 2002).

CBT Homework Examples:  Self-monitoring  Trigger sheet  Recognizing assertiveness  Goal setting  Coping records  Awareness of problem thinking

Motivation and homework completion on cocaine use during treatment High motivation Low motivation

Conclusions  In cocaine-dependent patients, the combination of naltrexone 50 mg and Relapse Prevention therapy was effective in reducing cocaine use.  Treatment integrity measures showed evidence of therapy adherence and discriminability.  For CBT, a positive relationship between homework compliance and cocaine outcome was found. Motivation to change affected the direction of this relationship.  Need to replicate and extend to determine the robustness of this treatment.

Naltrexone Studies  Naltrexone and relapse prevention treatment for cocaine-dependent patients  Naltrexone and relapse prevention treatment for cocaine-alcohol dependent patients

Study Design Pharmacotherapy (Naltrexone) 0 mg 50 mg Psycho- Therapy Drug Counseling (DC) Relapse Prevention (RP)

TABLE 1 Characteristics of Participants in Each Treatment Group a Attended at least six weeks of treatment.

Retention Log Rank (df = 3) = 3.62, ns.

Cocaine Use Time x Therapy F (11, 332) = 2.09, p < 0.02.

Conclusions  Naltrexone did not reduce cocaine or alcohol use in this sample of dually-dependent patients.  Patients receiving Drug Counseling used less cocaine over time than those receiving Relapse Prevention.  Naltrexone’s lack of efficacy in treating this type of comorbidity, also reported by Hersh et al., 1998, may be due to greater impairment in this population.

Combined Treatment for Cocaine-Alcohol Dependence R01 DA15801 Pharmacotherapy (Naltrexone) 0 mg 100 mg Behavior Therapy Relapse Prevention (RP) RP + Conting. Manag. Proc

Results: % cocaine abstinent Ss Pettinati et al, 2004 Men Women

Conclusions  Among cocaine dependent patients: Naltrexone 50mg reduced cocaine use was well tolerated worked best with CBT  Among cocaine-alcohol dependent patients: Naltrexone 50 mg ineffective with/without CBT

Future Considerations  Optimal dosing  Combination pharmacotherapy  Relapse prevention vs abstinence initiation  Enhancing compliance, increasing motivation  Patients’ conceptualization of behavior therapy + medication

Treatment expectancies